clopamide | 636-54-4

• 物质功能分类: 分析化学 - 标准品 - 药典标准品和杂质标准品
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: clopamide
• 英文别名: ZINC00020256；SJ000286007；4-Chlor-3-sulfamyl-N--benzoesaeureamid；N--3-sulfamyl-4-chlor-benzoesaeureamid；N-(cis-2,6-Dimethyl-piperidyl-(1))-3-sulfamyl-4-chlor-benzoesaeureamid；4-chloro-N-[(2R,6S)-2,6-dimethylpiperidin-1-yl]-3-sulfamoylbenzamide
• CAS: 636-54-4
• 化学式: C₁₄H₂₀ClN₃O₃S
• 分子量: 345.85
• InChiKey: LBXHRAWDUMTPSE-AOOOYVTPSA-N

物化性质

• 熔点：
  248-249℃
• 密度：
  1.39±0.1 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿（轻微、加热、超声处理）、甲醇（轻微）

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  101
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 危险品标志：
  Xn
• 安全说明：
  S36
• 危险类别码：
  R42/43
• WGK Germany：
  3
• 海关编码：
  2935009090
• 储存条件：
  2-8°C

制备方法与用途

生物活性

Clopamide 是一种具有口服活性的噻嗪类利尿剂，能够抑制钠耦合的氯离子共转运蛋白 SLC12A3。它可用于高血压和心力衰竭的研究。

体外研究

Clopamide 被肾管细胞主动分泌，其真肾小管排泄分数（TTEF）值为 10%。

体内研究

口服给予 Clopamide (0.5 mg/kg) 后，它会减弱狗对缓激肽的静脉收缩反应。同时，通过局部连续输注环孢素 A（1-10 μg/min），这种效应可以进一步增强。

反应信息

• 作为反应物：
  描述：

  clopamide 在 4-二甲氨基吡啶 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三氟乙酸 作用下， 生成 ({6-[2-Chloro-5-(2,6-dimethyl-piperidin-1-ylcarbamoyl)-benzenesulfonylaminocarbonyl]-naphthalen-2-yl}-difluoro-methyl)-phosphonic acid
  参考文献：
  名称：

  Acylsulfonamide-containing PTP1B inhibitors designed to mimic an enzyme-bound water of hydration

  摘要：

  Previously, it had been reported that 6-(phosphonodifluoromethyl)-2-naphthoic acid binds to the protein-tyrosine phosphatase PTP1B with its 2-carboxyl group interacting only indirectly through a bridging water molecule. Reported herein is a family of new analogues that utilize acylsulfonamido functionality both to mimic this water of hydration and to provide an additional new site for elaboration not found in the parent carboxyl-containing analogue. Target acylsulfonamides were prepared in two steps from commercially available primary sulfonamides, which were selected based on in silico screening for their potential ability to interact with one of three binding surfaces proximal to the PTP1B catalytic site. In general, modest potency enhancements were observed. Arylacylsulfonamides represent a structure-based extension of inhibitor design that may have broader utility in the development of PTP1B inhibitors. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00635-8

文献信息

• [EN] PHARMACEUTICAL COMPOSITIONS WITH IMPROVED DISSOLUTION<br/>[FR] COMPOSITIONS PHARMACEUTIQUES A DISSOLUTION AMELIOREE
  申请人：TRANSFORM PHARMACEUTICALS INC

  公开号：WO2004000284A1

  公开（公告）日：2003-12-31

  The invention relates to methods of screening mixtures containing a pharmaceutical compound an excipient to identify properties of the pharmaceutical compound/excipient combination that retard solid-state nucleation. The invention further relates to increasing the solubility, dissolution and bioavailability of a drug with low solubility in gastric fluids conditions by combining the drug with a recrystallization/precipitation retardant and an optional enhancer.

  本发明涉及筛选包含药物化合物和赋形剂的混合物的方法，以识别延缓固态成核的药物化合物/赋形剂组合的特性。该发明还涉及通过将药物与再结晶/沉淀抑制剂和可选增效剂结合，来增加低溶解度药物在胃液条件下的溶解度、溶出性和生物利用度。
• Pharmaceutical compositions with improved dissolution
  申请人：Tawa Mark

  公开号：US20060134198A1

  公开（公告）日：2006-06-22

  The invention relates to methods of screening mixtures containing a pharmaceutical compound and an excipient to identify properties of the pharmaceutical compound/excipient combination that retard solid-state nucleation. The invention further relates to increasing the solubility, dissolution and bioavailability of a drug with low solubility in gastric fluids conditions by combining the drug with a precipitation retardant and an optional enhancer.

  本发明涉及筛选混合物的方法，该混合物含有药物化合物和赋形剂，以识别药物化合物/赋形剂组合的性质，以延缓固态成核。本发明还涉及通过将药物与沉淀抑制剂和可选增效剂结合，在胃液条件下增加低溶解度药物的溶解度、溶出度和生物利用度的方法。
• Pharmaceutical oral-controlled release multiple-units formulation
  申请人：BENZON PHARMA A/S

  公开号：EP0106443A2

  公开（公告）日：1984-04-25

  A pharmaceutical oral controlled release multiple-units formulation in which the individual units comprise coated units containing an active substance which is subject to controlled release as a result of coating of the units with a water-insoluble, but water-diffusable controlled release coating, the units additionally comprising particles of an active substance adhered to the surface of the controlled release coating in a substantially uniform layer, the particles being at least one power of ten smaller than the coated units. The active substance in the units may be potassium chloride, and that adhered to the surface of the controlled release coating may be a diuretic.

  一种药物口服控释多单元制剂，其中单个单元包括含有活性物质的包衣单元，该活性物质通过在单元上包覆一层不溶于水但可在水中扩散的控释包衣而得到控释，单元还包括附着在控释包衣表面的活性物质颗粒，该颗粒基本上是均匀的一层，颗粒比包衣单元至少小十分之一。 单元中的活性物质可以是氯化钾，附着在控释包衣表面的活性物质可以是利尿剂。
• Arzneimittellösungen und Verfahren zu deren Herstellung
  申请人：Dr. Rentschler Arzneimittel GmbH & Co.

  公开号：EP0023355B1

  公开（公告）日：1985-11-21
• PHARMACEUTICAL COMPOSITIONS WITH IMPROVED DISSOLUTION
  申请人：Transform Pharmaceuticals, Inc.

  公开号：EP1515703A1

  公开（公告）日：2005-03-23